~~<i id='868C986CD2'><strike id='868C986CD2'><tt id='868C986CD2'><pre id='868C986CD2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：Wikipedia 2025-09-03 12:10:58 - browse：932

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Readout Newsletter: Merck, J&J, and long Covid

hotspot

focus

entertainment

leisure time

explore

PriscillaChanandMarkZuckerbergonstage,virtually,atthe2023STATSummit.STATMarkZuckerbergandPriscillaCh

WSS

Research misconduct: Proposed new rules face resistance

Eli Lilly to pay $200M for Beam’s stake in gene

First Opinion Podcast: How to protect health care in times of war

Telehealth options flood the market as retailers push virtual care

AI generated plenty of interest at JPM but not a lot of trust

Readout Newsletter: New research from Sanofi, Regeneron, etc.

entertainment

explore

hotspot

Affirmative action in medical school literally saved lives

CDC recommends rationing of RSV shot due to shortages

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Medical records are filled with copy

FDA has safety concerns on CRISPR

United colonoscopy coverage change 'may cost lives,' doctors say

NIH director takes cautious approach to Biden drug pricing priority

Jerome Adams on the need for new antivirals for Covid

AI generated plenty of interest at JPM but not a lot of trust

focus

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Cassava reveals details — and problems — with Alzheimer's study

Why doctors need education on FDA device approval process

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

My yearlong odyssey to get my son’s ADHD medication covered

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

entertainment

leisure time

explore

explore